The next big thing for global Pharma - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

The next big thing for global Pharma

Oct 15, 2009

Emerging economies have been garnering a lot of interest of late as far as investments are concerned. Not only are the developed economies mired in a recession but the prospects also do not look too enthusing in the near future atleast. In stark contrast, emerging economies led by China and India are expected to post strong growth rates, a phenomenon which will be witnessed in the global pharmaceutical industry as well. Thus, in this article, we shall take a look at what is driving the growth of branded generics in these emerging markets. Domestic pharma's branded focus

Indian pharma companies were at the forefront in capitalising on the branded generics opportunity. As a result, their exports strategy not only revolved around selling generic medicines in the developed nations of the US and Europe but also in the semi or less regulated markets of Asia, Africa, Russia and the CIS. The latter especially were lucrative because generic medicines there can be branded and hence pushed through doctors. This could not be done in the US and Europe, which are heavily regulated. Here, generic medicines cannot be branded unless companies can show that their versions are more effective due to superior technology or a superior delivery mechanism. However, in the semi or less regulated markets, generics can be branded just like they are in India. But since they are not subject to price control as in India, the revenue and profit potential is that much higher.

Domestic companies such as Ranbaxy, Dr.Reddy's, Sun Pharma, Glenmark, Lupin, Cadila and the like are looking to enhance their presence in these regions especially when the US and European generics markets in recent times have been marred by intense competition and price erosion.

Global innovators jumping the bandwagon

Another breed of pharma companies have also realized the potential of branded generics and are looking to grab a slice of the branded generics pie. We are talking about the global innovators such as Pfizer Inc., GSK Plc, Sanofi-Aventis and the like, which previously focused on developing patented drugs. There are various reasons for wanting to dabble in generics as well. First is that their own research pipelines are drying up with not much to show for the amount of money invested in R&D. Secondly, many of their blockbusters are going off patent which would mean a huge drop in sales and profits. Thirdly, governments across the world are looking to cut healthcare costs by encouraging the use of generics. Little wonder than that Big Pharma which hitherto was averse to generics, is now finding itself joining hands with Indian generic players to foray into emerging markets. Case in point would be Pfizer Inc.'s partnership with Aurobindo Pharma and GSK Pharma's alliance with Dr.Reddy's amongst others.

Going forward...

We believe that branded generics will play an important role in driving the growth of the global pharmaceutical market. This is not to say that the US generics market will not witness growth as there are many patent expiries on the anvil. But because margins in the US are low, the emerging markets will form an important business for domestic pharma companies. As far as the global pharma markets are concerned, while the US pharma market is projected to register a decline of 1%-2% in 2009, the top five European markets (France Germany, the UK, Italy and Spain) are forecast to grow at 3%-4% in 2009.

This means that emerging markets (including India and China) will be the next frontier and these markets, which logged in a healthy growth of 12% in 2008, are expected to grow collectively at 13% to 16% up to 2013. Infact, the seven emerging markets (China, Brazil, India, South Korea, Mexico, Turkey and Russia) are expected to contribute 40% to the global market growth from 2009 to 2013 (Source: Dr.Reddy's annual report). Thus, akin to other industries, the pharma industry in the emerging markets hold huge potential and Indian pharma companies which are firmly entrenched in these markets stand to benefit immensely from the same.

Equitymaster requests your view! Post a comment on "The next big thing for global Pharma". Click here!

1 Responses to "The next big thing for global Pharma"

santushta

Oct 28, 2009

I have nt at received Midcapselect recommendatio for this wednsday 28/10/09

Like 
  
Equitymaster requests your view! Post a comment on "The next big thing for global Pharma". Click here!

More Views on News

PIRAMAL ENTERPRISES Share Price Down by 5%; BSE HEALTHCARE Index Down 1.2% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

PIRAMAL ENTERPRISES share price is trading down by 5% and its current market price is Rs 1,588. The BSE HEALTHCARE is down by 1.2%. The top gainers in the BSE HEALTHCARE Index are NATCO PHARMA (up 0.9%) and FORTIS HEALTHCARE (up 0.9%). The top losers is PIRAMAL ENTERPRISES (down 5.1%).

BIOCON Share Price Down by 10%; BSE HEALTHCARE Index Down 1.2% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

BIOCON share price is trading down by 10% and its current market price is Rs 424. The BSE HEALTHCARE is down by 1.2%. The top gainers in the BSE HEALTHCARE Index are AUROBINDO PHARMA (up 1.7%) and FORTIS HEALTHCARE (up 0.9%). The top losers is BIOCON (down 10.1%).

BIOCON Share Price Down by 6%; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Jan 22, 2021 | Updated on Jan 22, 2021

BIOCON share price is trading down by 6% and its current market price is Rs 424. The BSE HEALTHCARE is down by 0.2%. The top gainers in the BSE HEALTHCARE Index are PROCTER & GAMBLE HEALTH (up 2.6%) and JUBILANT LIFE SCIENCES (up 1.5%). The top losers is BIOCON (down 6.1%).

More Views on News

Most Popular

Why Gold Hit Lower Circuit (Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks (Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021 (Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond (Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Jan 22, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS